Settlement ends arbitration, new licence simplifies future royalties
Aurora Spine Corporation announced Friday it has resolved a long‑running dispute with SILIF Corporation over a U.S. patent for a sacroiliac (SI) joint implant, entering a new four‑year non‑exclusive licence and agreeing to a settlement that will see arbitration dismissed.
The licence covers U.S. Patent #9,451,986, titled "Percutaneous sacroiliac joint implant and method for surgically inserting and securing the implant into the sacroiliac joint," and replaces the previous agreement under which Aurora Spine developed its SiLO TFX Transfixing SI Joint System. The new licence takes effect on Aug. 11, 2026.
The settlement package includes several elements intended to simplify the parties' commercial relationship and Aurora Spine's accounting of royalty obligations.
- Cash payment of US$283,000 from Aurora Spine to SILIF;
- Return of 2,700,000 shares to Aurora Spine;
- Extinguishment of a related note payable to Aurora Spine from SILIF;
- Dismissal of the arbitration that had been initiated under the prior licence agreement.
Company documents state the settlement provides a "simplified royalty calculation" for future sales of the SiLO TFX system.
Insider loan increases liquidity but raises related‑party considerations
In a parallel financing move, an insider of the company has agreed to increase the principal available under an existing loan by US$600,000, bringing the total principal owing to the insider to US$2.2 million. The loan is evidenced by a promissory note bearing interest at 4.5% per annum and matures on July 11, 2029.
The company said it intends to use proceeds from the loan for general corporate purposes. Aurora Spine, Inc., the company's wholly owned subsidiary, continues to guarantee and secure the obligations under the note. The loan can be prepaid, in whole or in part, without penalty.
The promissory note includes an acceleration clause: upon a change of control of the company, the maturity date can be accelerated and the note declared due and payable in full upon written request by the holder. The originator describes the loan as a "related party transaction" under Multilateral Instrument rules.
Local and investor implications
For investors and observers in this region, the settlement removes a legal overhang that could complicate revenue recognition and royalty payments tied to the SiLO TFX product. Returning shares and extinguishing the related receivable from SILIF are changes that may improve balance‑sheet clarity, while the cash payment creates an immediate cash outflow.
The increased insider lending provides additional near‑term liquidity, but also highlights the company's reliance on related‑party financing. The acceleration clause on a change of control means that any future transaction that alters ownership could trigger debt repayment requirements to the insider.
| Item | Detail |
|---|---|
| Patent licence | US Patent #9,451,986 — 4‑year non‑exclusive licence from Aug. 11, 2026 |
| Settlement cash | US$283,000 paid to SILIF |
| Shares returned | 2,700,000 shares to Aurora Spine |
| Insider loan total | US$2.2 million; interest 4.5% maturing July 11, 2029 |
Investors will likely watch upcoming regulatory filings and the company's financial statements for further detail on how the settlement and loan affect reported liabilities and royalties. The company has advised that the arbitration proceedings related to the previous licence are being dismissed as part of the settlement.
While Aurora Spine is incorporated and operating in the medical device sector far from Ontario's municipal operations, the developments are relevant to local shareholders and stakeholders who follow corporate governance, related‑party financing and the commercial prospects of device makers whose products reach hospitals and surgical centres across North America.
